Additionally, the 36-month beta value for SNDX is 0.74. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 2
Company’s 36-month beta value is 0.74.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 2 as “overweight,” 1 as
Company’s 36-month beta value is 0.74.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 2 as “overweight,” 1 as
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) has experienced a rise in its stock price by 0.52 compared to its previous closing price of 9.64. However, the
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) has seen a decline in its stock price by -2.84 in relation to its previous close of 10.90. However, the
© 2024, Powered by Smart TechOne